Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia

Psychiatric Services

Volumn 58, Issue 4, 2007, Pages 482-488

  Shi, Lizheng ^a   Ascher Svanum, Haya ^b   Zhu, Baojin ^b   Faries, Douglas ^b   Montgomery, William ^b   Marder, Stephen R ^c,d  

^a TULANE UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE DECANOATE; HALOPERIDOL; ILLICIT DRUG; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL RECORD; MENTAL DISEASE; MULTICENTER STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF REPORT; SOCIOECONOMICS; TREATMENT DURATION;

EID: 34247367267     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.2007.58.4.482     Document Type: Article

References (34)

1. Cramer JA, Rosenheck R: Compliance with medication regimens for mental and physical disorders. Psychiatric Services 49:196-201, 1998
2. Diaz E, Levine HB, Sullivan MC, et al: Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. Journal of Psychiatry and Neuroscience 26:325-329, 2001
3. Kane JM: Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Journal of Clinical Psychiatry 64(suppl 16):34-40, 2003
4. Marder SR: Overview of partial compliance. Journal of Clinical Psychiatry 64(suppl 16):3-9, 2003
5. Love RC: Strategies for increasing treatment compliance: the role of long-acting antipsychotics. American Journal of Health System Pharmacy 59(22 suppl 8):S10-S15, 2002
6. Kane JM, Leucht S, Carpenter D, et al: Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders: introduction: methods, commentary, and summary. Journal of Clinical Psychiatry 64(suppl 12):5-19, 2003
7. Kane JM, Aguglia E, Altamura AC, et al: Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Journal of the European College of Neuropsychopharmacology 8:55-66, 1998
8. Barnes TR, Curson DA: Long-term depot antipsychotics: a risk-benefit assessment. Drug Safety 10:464-479, 1994
9. Glazer WM, Kane JM: Depot neuroleptic therapy: an underutilized treatment option. Journal of Clinical Psychiatry 53:426-433, 1992
10. Faries D, Asher-Svanum H, Zhu B, et al: Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5(1):26, 2005
11. Ascher-Svanum H, Zhu B, Faries D, et al: A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Annals of General Hospital Psychiatry 3:11, 2004
12. Ascher-Svanum H, Faries D, Zhu B, et al: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Journal of Clinical Psychiatry 67:453-460, 2006
13. Lehman AF, Fischer EP, Postrado L: The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Schizophrenia Bulletin 29:247-256, 2003
14. Davis JM, Chen N: The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. Journal of Clinical Psychiatry 62:757-771, 2001
15. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134:382-389, 1979
16. Endicott J, Spitzer RL, Fleiss JL, et al: The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 33:766-771, 1976
17. Gilmer TP, Dolder CR, Lacro JP, et al: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161:692-699, 2004
18. Lehman AF, Lieberman JA, Dixon LB, et al: Practice guideline for the treatment of patients with schizophrenia, 2nd ed. American Journal of Psychiatry 161(Feb suppl):1-56, 2004
19. Fenton WS, Blyler CR, Heinssen RK: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin 23:637-651, 1997
20. Bhanji NH, Chouinard G, Margolese HC: A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Journal of the European College of Neuropsychopharmacology 14(2):87-92, 2004
21. Haro JM, Edgell ET, Frewer P, et al: The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatrica Scandinavica Supplementum 416:7-15, 2003
22. Mond J, Morice R, Owen C, et al: Use of antipsychotic medications in Australia between July 1995 and December 2001. Australian and New Zealand Journal of Psychiatry 37:55-61, 2003
23. Rosenheck RA, Desai R, Steinwachs D, et al: Benchmarking treatment of schizophrenia: a comparison of service delivery by the national government and by state and local providers. Journal of Nervous and Mental Disease 188:209-216, 2000
24. Price N, Glazer W, Morgenstern H: Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. American Journal of Psychiatry 142:1491-1492, 1985
25. Kreyenbuhl J, Zito JM, Buchanan RW, et al: Racial disparity in the pharmacological management of schizophrenia. Schizophrenia Bulletin 29:183-193, 2003
26. Kuno E, Rothbard AB: Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry 159:567-572, 2002
27. Covell NH, Jackson CT, Evans AC, et al: Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophrenia Bulletin 28:17-29, 2002
28. Strakowski SM, Flaum M, Amador X, et al: Racial differences in the diagnosis of psychosis. Schizophrenia Research 21:117-124, 1996
29. Valenstein M, Copeland LA, Owen R, et al: Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. Journal of Clinical Psychiatry 62:545-551, 2001
30. Blow FC, Zeber JE, McCarthy JF, et al: Ethnicity and diagnostic patterns in veterans with psychoses. Social Psychiatry and Psychiatric Epidemiology 39:841-851, 2004
31. Citrome L, Levine J, Allingharn B: Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacology Bulletin 32:321-326, 1996
32. Patrick V, Levin E, Schleifer S: Antipsychotic polypharmacy: is there evidence for its use? Journal of Psychiatric Practice 11:248-257, 2005
33. Shireman TI, Svarstad BL, Sweeney JK: Validity of claims data for long-acting injectable medications. Journal of Pharmacoepidemiology 7:41-55, 1999
34. Svarstad BL, Shireman TI, Sweeney JK: Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services 52:805-811, 2001